007足球比分即时网

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

03-252024

Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor α

Guangzhou, China -- Bio-Thera Solutions(688177:SH), a commercial-stage biopharmaceutical company developing a pipelineof...
03-182024

Bio-Thera Solutions Partners with SteinCares to Market Two Biosimilars in LATAM

GUANGZHOU, China and San José, Costa Rica- Bio-Thera Solutions, a commercial-stagebiopharmaceutical company developing i...
02-012024

Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026, a Monoclonal Antibody Targeting OX40, in Patients with Moderate to Severe Atopic Dermatitis

Guangzhou, China -- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline o...

上一页 ···12 13 14 15 16 ··· 下一页